ASTM F 1983 : 2014
Superseded
A superseded Standard is one, which is fully replaced by another Standard, which is a new edition of the same Standard.
View Superseded by
Standard Practice for Assessment of Selected Tissue Effects of Absorbable Biomaterials for Implant Applications
Hardcopy , PDF
24-04-2023
English
02-02-2015
This practice provides experimental protocols for biological assays of tissue reactions to absorbable biomaterials for implant applications.
Committee |
F 04
|
DocumentType |
Standard Practice
|
Pages |
6
|
PublisherName |
American Society for Testing and Materials
|
Status |
Superseded
|
SupersededBy | |
Supersedes |
1.1This practice provides experimental protocols for biological assays of tissue reactions to absorbable biomaterials for implant applications. This practice applies only to absorbable materials with projected clinical applications in which the materials will reside in bone or soft tissue longer than 30 days and less than three years. Other standards with designated implantation times are available to address shorter time periods. Careful consideration should be given to the appropriateness of this practice for slowly degrading materials that will remain for longer than three years. It is anticipated that the tissue response to degrading biomaterials will be different from the response to nonabsorbable materials. In many cases, a chronic inflammatory response may be observed during the degradation phase, but the local histology should return to normal after absorption; therefore, the minimal tissue response usually equated with “biocompatibility” may require long implantations.
1.2The time period for implant absorption will vary depending on chemical composition implant size, implant location, and test subject species; therefore, the implantation times for examination of tissue response will be linked to the rate of absorption. No single implantation time is indicated in this practice.
1.3These protocols assess the effects of the material on the animal tissue in which it is implanted. The experimental protocols do not fully assess systemic toxicity, carcinogenicity, teratogenicity, or mutagenicity of the material. Other standards are available to address these issues.
1.4To maximize use of the animals in the study protocol, all toxicological findings should be recorded. There are some aspects of systemic toxicity, including effects of degradation products on the target organs, that can be addressed with this practice, and these effects should be documented fully.
1.5This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
ASTM F 3510 : 2021 | Standard Guide for Characterizing Fiber-Based Constructs for Tissue-Engineered Medical Products |
ASTM F 3089 : 2023 | Standard Guide for Characterization and Standardization of Polymerizable Collagen-Based Products and Associated Collagen-Cell Interactions |
ASTM F 2150 : 2019 | Standard Guide for Characterization and Testing of Biomaterial Scaffolds Used in Regenerative Medicine and Tissue-Engineered Medical Products |
ASTM F 2884 : 2021 | Standard Guide for Pre-clinical <emph type="bdit">in vivo</emph> Evaluation of Spinal Fusion |
ASTM F 2721 : 2009 : R2023 | Standard Guide for Preclinical <emph type="ital">in vivo</emph> Evaluation in Critical-Size Segmental Bone Defects |
ASTM F 3515 : 2021 | Standard Guide for Characterization and Testing of Porcine Fibrinogen as a Starting Material for Use in Biomedical and Tissue-Engineered Medical Product Applications |
ASTM F 2884 : 2012 | Standard Guide for Pre-clinical <emph type="bdit">in vivo</emph> Evaluation of Spinal Fusion (Withdrawn 2021) |
ASTM F 2902 : 2016 : EDT 1 | Standard Guide for Assessment of Absorbable Polymeric Implants |
ASTM F 2721 : 2009 : R2014 | Standard Guide for Pre-clinical <emph type="bdit">in vivo</emph> Evaluation in Critical Size Segmental Bone Defects |
ASTM F 2150 : 2013 | Standard Guide for Characterization and Testing of Biomaterial Scaffolds Used in Tissue-Engineered Medical Products |
ASTM F 3089 : 2014 | Standard Guide for Characterization and Standardization of Polymerizable Collagen-Based Products and Associated Collagen-Cell Interactions |
ASTM F 2212 : 2011 | Standard Guide for Characterization of Type I Collagen as Starting Material for Surgical Implants and Substrates for Tissue Engineered Medical Products (TEMPs) |
ASTM F 2883 : 2011 | Standard Guide for Characterization of Ceramic and Mineral Based Scaffolds used for Tissue-Engineered Medical Products (TEMPs) and as Device for Surgical Implant Applications (Withdrawn 2020) |
ASTM F 748 : 2016 | Standard Practice for Selecting Generic Biological Test Methods for Materials and Devices |
ASTM F 1904 : 1998 : R2003 | Standard Practice for Testing the Biological Responses to Particles In Vivo |
ASTM F 1906 : 1998 | Standard Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte, Proliferation, and Cell Migration |
ASTM F 1904 : 1998 : EDT 1 | Standard Practice for Testing the Biological Responses to Particles In Vivo |
ASTM F 763 : 2022 | Standard Practice for Short-Term Intramuscular Screening of Implantable Medical Device Materials |
ASTM F 1903 : 2010 | Standard Practice for Testing For Biological Responses to Particles <i>In Vitro</i> |
ASTM F 763 : 2004 : R2016 | Standard Practice for Short-Term Screening of Implant Materials |
ASTM F 1904 : 2014 | Standard Practice for Testing the Biological Responses to Particles <emph type="bdit" >in vivo</emph> |
ASTM F 1905 : 1998 | Standard Practice for Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity |
ASTM F 1408 : 1997 | Standard Practice for Subcutaneous Screening Test for Implant Materials |
ASTM F 1408 : 1997 : R2008 | Standard Practice for Subcutaneous Screening Test for Implant Materials |
ASTM F 1904 : 1998 : R2008 | Standard Practice for Testing the Biological Responses to Particles <i>in vivo</i> |
ASTM F 1903 : 1998 | Standard Practice for Testing for Biological Responses to Particles In Vitro |
ASTM F 1408 : 1997 : R2002 : EDT 1 | Standard Practice for Subcutaneous Screening Test for Implant Materials |
ASTM F 763 : 1999 | Standard Practice for Short-Term Screening of Implant Materials |
ASTM F 1905 : 1998 : R2003 | Standard Practice for Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity (Withdrawn 2011) |
ASTM F 1903 : 2018 | Standard Practice for Testing for Cellular Responses to Particles <emph type="bdit" >in vitro</emph> |
ASTM F 1906 : 1998 : R2003 | Standard Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte, Proliferation, and Cell Migration (Withdrawn 2011) |
ASTM F 1408 : 1997 : R2013 | Standard Practice for Subcutaneous Screening Test for Implant Materials |
Access your standards online with a subscription
Features
-
Simple online access to standards, technical information and regulations.
-
Critical updates of standards and customisable alerts and notifications.
-
Multi-user online standards collection: secure, flexible and cost effective.